Compare Stocks: DVAX, PRAX, ALKS, and IOVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$43.63 -1.2%	$44.43	$27.00 ▼ $55.67	$7.32B	0.32	2.19 million shs	884,579 shs
DVAX Dynavax Technologies	$15.50	$15.51	$9.20 ▼ $15.73	$1.82B	0.97	2.20 million shs	N/A
IOVA Iovance Biotherapeutics	$14.09 -0.4%	$10.94	$1.76 ▼ $15.37	$6.38B	0.76	16.39 million shs	7.75 million shs
PRAX Praxis Precision Medicines	$252.96 -2.3%	$310.36	$154.45 ▼ $392.70	$7.06B	2.79	547,313 shs	371,617 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+5.85%	+6.96%	-17.51%	+40.33%
DVAX Dynavax Technologies	0.00%	0.00%	0.00%	0.00%	+52.71%
IOVA Iovance Biotherapeutics	0.00%	+3.45%	+30.46%	+182.36%	+555.35%
PRAX Praxis Precision Medicines	0.00%	+4.63%	-10.23%	-22.24%	+37.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$43.63 -1.2%	$44.43	$27.00 ▼ $55.67	$7.32B	0.32	2.19 million shs	884,579 shs
DVAX Dynavax Technologies	$15.50	$15.51	$9.20 ▼ $15.73	$1.82B	0.97	2.20 million shs	N/A
IOVA Iovance Biotherapeutics	$14.09 -0.4%	$10.94	$1.76 ▼ $15.37	$6.38B	0.76	16.39 million shs	7.75 million shs
PRAX Praxis Precision Medicines	$252.96 -2.3%	$310.36	$154.45 ▼ $392.70	$7.06B	2.79	547,313 shs	371,617 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+5.85%	+6.96%	-17.51%	+40.33%
DVAX Dynavax Technologies	0.00%	0.00%	0.00%	0.00%	+52.71%
IOVA Iovance Biotherapeutics	0.00%	+3.45%	+30.46%	+182.36%	+555.35%
PRAX Praxis Precision Medicines	0.00%	+4.63%	-10.23%	-22.24%	+37.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.68	Moderate Buy	$54.47	24.85% Upside
DVAX Dynavax Technologies	1.50	Reduce	N/A	N/A
IOVA Iovance Biotherapeutics	2.62	Moderate Buy	$13.20	-6.32% Downside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$630.42	149.22% Upside

Current Analyst Ratings Breakdown

Latest DVAX, PRAX, ALKS, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	ALKS Alkermes	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$55.00
10/16/2026	PRAX Praxis Precision Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$700.00
10/15/2026	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1,201.00
10/14/2026	PRAX Praxis Precision Medicines	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$706.00
10/13/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$15.00 ➝ $18.00
10/8/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$6.00 ➝ $11.00
10/6/2026	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1,201.00
10/6/2026	PRAX Praxis Precision Medicines	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$810.00 ➝ $826.00
9/30/2026	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$14.00 ➝ $18.00
9/29/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/29/2026	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$9.00 ➝ $20.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	4.96	$1.67 per share	26.06	$11.02 per share	3.96
DVAX Dynavax Technologies	$330.51M	5.51	$0.16 per share	97.88	$4.54 per share	3.41
IOVA Iovance Biotherapeutics	$263.50M	24.22	N/A	N/A	$1.76 per share	8.01
PRAX Praxis Precision Medicines	$8.55M	826.04	N/A	N/A	$34.85 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	101.46	140.74	N/A	3.96%	4.15%	2.19%	11/3/2026 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.37	N/A	31.63	N/A	-13.13%	7.18%	4.08%	N/A
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)

Latest DVAX, PRAX, ALKS, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	PRAX Praxis Precision Medicines	-$3.54	N/A	N/A	N/A	$0.13 million	N/A
11/5/2026	Q3 2026	IOVA Iovance Biotherapeutics	-$0.0847	N/A	N/A	N/A	$115.53 million	N/A
11/3/2026	Q3 2026	ALKS Alkermes	-$0.0809	N/A	N/A	N/A	$463.61 million	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
DVAX Dynavax Technologies	0.41	7.62	6.94
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
PRAX Praxis Precision Medicines	N/A	15.73	15.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
DVAX Dynavax Technologies	96.96%
IOVA Iovance Biotherapeutics	77.03%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
DVAX Dynavax Technologies	2.98%
IOVA Iovance Biotherapeutics	7.80%
PRAX Praxis Precision Medicines	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
DVAX Dynavax Technologies	350	117.43 million	113.93 million	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable
PRAX Praxis Precision Medicines	168	27.92 million	27.08 million	Optionable

DVAX, PRAX, ALKS, and IOVA Headlines

Recent News About These Companies

Praxis Precision Medicines (NASDAQ:PRAX) Stock Jumps 7.1% - Time to Buy?

October 19, 2026 | marketbeat.com

Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?

October 19, 2026 | finance.yahoo.com

JPMorgan Chase & Co. Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX)

October 18, 2026 | americanbankingnews.com

Praxis Precision Medicines (PRAX) Receives a New Rating from a Top Analyst

October 17, 2026 | theglobeandmail.com

HC Wainwright Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)

October 17, 2026 | americanbankingnews.com

Praxis Precision Medicines (NASDAQ:PRAX) Stock Rating Cut to "Sell" at Wall Street Zen

October 17, 2026 | americanbankingnews.com

Praxis Precision Medicines (NASDAQ:PRAX) Stock Rating Cut to Sell at Wall Street Zen

October 17, 2026 | marketbeat.com

JP Morgan Initiates Coverage of Praxis Precision Medicines at Overweight

October 16, 2026 | msn.com

UBS initiates coverage of Praxis Precision Medicines with buy

October 16, 2026 | msn.com

JPMorgan Initiates Praxis Precision Medicines at Overweight With $700 Price Target

October 16, 2026 | marketscreener.comM

Praxis Precision Medicines (NASDAQ:PRAX) Stock Rated Overweight in New Coverage at JPMorgan Chase & Co.

October 16, 2026 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Has Consensus Price Target of $610.95

October 16, 2026 | americanbankingnews.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Has Average Price Target of $610.95

October 16, 2026 | marketbeat.com

UBS Initiates Praxis Precision Medicines at Buy With $706 Price Target

October 15, 2026 | marketscreener.comM

Praxis Precision Medicines (NASDAQ:PRAX) Stock Rating Reaffirmed as "Buy" by HC Wainwright

October 15, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Stock Acquired by Rep. Gilbert Ray Cisneros, Jr.

October 14, 2026 | marketbeat.com

BTIG raised its target for Praxis Precision Medicines stock to USD 826

October 13, 2026 | ad-hoc-news.deA

Praxis Precision Medicines stock fell 1.21 percent as Q2 costs rose

October 7, 2026 | ad-hoc-news.deA

Praxis Precision Medicines (NASDAQ:PRAX) Given "Buy" Rating at HC Wainwright

October 6, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Target Raised at BTIG Research

October 6, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Stock Falls 5.1% - Here's What Happened

October 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DVAX, PRAX, ALKS, and IOVA Company Descriptions

Alkermes NASDAQ:ALKS

$43.63 -0.55 (-1.24%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$43.60 -0.03 (-0.06%)

As of 10/23/2026 07:30 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Dynavax Technologies NASDAQ:DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Iovance Biotherapeutics NASDAQ:IOVA

$14.09 -0.05 (-0.35%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$14.08 -0.02 (-0.11%)

As of 10/23/2026 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Praxis Precision Medicines NASDAQ:PRAX

$252.96 -5.96 (-2.30%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$252.81 -0.15 (-0.06%)

As of 10/23/2026 07:37 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DVAX, PRAX, ALKS, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DVAX, PRAX, ALKS, and IOVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DVAX, PRAX, ALKS, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DVAX, PRAX, ALKS, and IOVA Company Descriptions

Alkermes NASDAQ:ALKS

Dynavax Technologies NASDAQ:DVAX

Iovance Biotherapeutics NASDAQ:IOVA

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DVAX, PRAX, ALKS, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DVAX, PRAX, ALKS, and IOVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DVAX, PRAX, ALKS, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DVAX, PRAX, ALKS, and IOVA Company Descriptions

Alkermes NASDAQ:ALKS

Dynavax Technologies NASDAQ:DVAX

Iovance Biotherapeutics NASDAQ:IOVA

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools